Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Scinai Immunotherapeutics ( (SCNI) ) has shared an update.
Scinai Immunotherapeutics Ltd. announced the resignation of two board members, Prof. Avner Rotman and Dr. Morris Laster, effective December 31, 2025, as part of cost-cutting measures. Additionally, the company plans to replace its current accounting firm, PwC, with Ziv Haft to further reduce costs, pending shareholder approval.
Spark’s Take on SCNI Stock
According to Spark, TipRanks’ AI Analyst, SCNI is a Neutral.
Scinai Immunotherapeutics is undergoing a financial recovery but faces significant challenges such as negative cash flows and high debt levels. The stock shows neutral technical indicators, suggesting moderate market confidence. Its attractive valuation might appeal to value investors, but the absence of dividends and financial risks may deter more conservative investors.
To see Spark’s full report on SCNI stock, click here.
More about Scinai Immunotherapeutics
Scinai Immunotherapeutics Ltd. operates in the biotechnology industry, focusing on immunotherapeutic products. The company is based in Jerusalem, Israel, and is involved in developing innovative solutions for immune-related conditions.
Average Trading Volume: 139,555
Technical Sentiment Signal: Sell
Current Market Cap: $934K
For a thorough assessment of SCNI stock, go to TipRanks’ Stock Analysis page.